Daily Stock Analysis, KDMN, Kadmon Holdings Inc, priceseries

Kadmon Holdings Inc. Daily Stock Analysis
Stock Information
Open
2.22
Close
2.21
High
2.27
Low
2.18
Previous Close
2.21
Daily Price Gain
0.00
YTD High
3.08
YTD High Date
Mar 22, 2019
YTD Low
2.02
YTD Low Date
Jan 2, 2019
YTD Price Change
-0.05
YTD Gain
-2.21%
52 Week High
4.39
52 Week High Date
Aug 31, 2018
52 Week Low
1.88
52 Week Low Date
Dec 31, 2018
52 Week Price Change
-1.86
52 Week Gain
-45.70%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 20. 2017
3.17
Jul 10. 2017
3.65
13 Trading Days
15.28%
Link
LONG
Sep 7. 2017
2.74
Sep 18. 2017
2.99
7 Trading Days
9.15%
Link
LONG
Jan 11. 2018
3.87
Feb 2. 2018
5.15
15 Trading Days
33.03%
Link
LONG
Mar 8. 2018
3.78
Mar 26. 2018
4.29
12 Trading Days
13.39%
Link
LONG
Aug 21. 2018
3.44
Sep 5. 2018
3.87
10 Trading Days
12.61%
Link
LONG
Feb 14. 2019
2.26
Mar 6. 2019
2.67
13 Trading Days
18.24%
Link
Company Information
Stock Symbol
KDMN
Exchange
NYSE
Company URL
http://www.kadmon.com
Company Phone
212-308-6000
CEO
Harlan W. Waksal
Headquarters
New York
Business Address
450 EAST 29TH STREET, NEW YORK, NY 10016
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001557142
About

Kadmon Holdings, Inc. is a biopharmaceutical company, which discovers, develops, and commercializes small molecules and biologics. It develops product candidates in a number of indications within autoimmune and fibrotic disease, oncology, and genetic disease. It offers ribavirin tablets and capsules, phentermine and topiramate extended-release capsules, and tetrabenazine tablets. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.

Description

Kadmon Holdings, LLC, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics to address unmet medical needs. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; co-promotes a product for chronic weight management; distributes products for chorea, cytomegalovirus retinitis, and for the prevention of CMV disease. It is also developing product candidates in autoimmune and fibrotic diseases, oncology, and genetic diseases. The company is headquartered in New York, New York.